Antimicrobial action and pharmacokinetics/pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance

Journal of Chemotherapy

Volumn 11, Issue 6, 1999, Pages 426-439

  Schentag, J J ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

Aminoglycosides; Area under the inhibitory concentration curve; Beta lactams; Pharmacodynamics; Pharmacokinetics; Quinolones; Resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; ERADICATION THERAPY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; RESPIRATORY TRACT INFECTION;

EID: 0033378518     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.6.426     Document Type: Conference Paper

References (44)

1. 1 Lynch JP III. Combination antibiotic therapy is appropriate for nosocomial pneumonia in the intensive care unit. Sem Resp Infect 1993; 8: 268-284.
2. 2 Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh infections. J Antimicrob Chemother 1991; 27(suppl C): 29-40.
3. 3 Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
4. 4 Leggett J, Fantin B, Ebert S, et al. Comparative antibiotic dose effect relations at several dosing intervals in murine pneumonitis and thigh infection models. J Infect Dis 1988; 159: 281-292.
5. 5 Dudley MN. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991; 91(suppl 6A): 45S-50S.
6. 6 Drusano GL. Human pharmacodynamics of beta lactams, aminoglycosides, and their combination. Scand J Infect Dis 1991; 74 suppl: 235-248.
7. 7 Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to MIC. J Infect Dis 1987; 155: 93-99.
8. 8 Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I) Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP, Ann Pharmacother 1991; 25: 1050-1057.
9. 9 Luzier A, Goss TF, Cumbo TJ, Schentag JJ. Mathematical examination of dual individualization principles (III) Development of a scoring system for pneumonia staging and quantitation of response to antibiotics: results in cefmenoxime treated patients. Ann Pharmacother 1992; 26: 1358-1364.
10. 10 Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, Schentag JJ. Mathematical examination of dual individualization principles (II) The rate of bacterial eradication at the same area under the inhibitory curve (AUIC) is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother 1994; 28: 863-868.
11. 11 McCormack JP, Schentag JJ. The potential impact of quantitative susceptibility tests on the design of aminoglycoside regimens. Drug Intell Clin Pharm 1987; 21: 187-191.
12. 12 Hyatt JM, McKinnon PS, Zimmer GZ, Schentag JJ. The importance of Pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143-160.
13. 13 Amsden GW, Ballow CH, Schentag JJ. Population pharmacokinetic methods to optimize antibiotic effects. Drug Investigat 1993; 5: 256-268.
14. 14 Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. The pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
15. th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA . Sept 17-20, 1995: 11(abstract).
16. 16 Nix DE, Schentag JJ. The role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12 hr cefotaxime alone and in combination with other antibiotics. Diag Microbiol Infect Dis 1995; 22: 71-76.
17. 17 Nix DE, Tyrrell R, Muller M. Pharmacodynamics of metronidazole determined by a time kill assay for trichomonas vaginalis. Antimicrob Agents Chemother 1995; 39: 1848-1852.
18. 18 Schentag JJ, Carr JR, Adelman MH, Birmingham MC, Zimmer GS, Paladino JA. Formulary management vs disease management. Infect Dis Clin Practice 1996; 5 (suppl 1): 1-6.
19. 19 Paladino JA, Fell RE. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother 1994; 28: 384-389.
20. 20 Schentag JJ, Ballow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diag Microbiol Infect Dis 1993; 16: 255-264.
21. 21 Paladino JA, Zimmer GS, Schentag JJ. The economic potential of dual individualization methodologies. Pharmacoeconomics 1996; 10: 539-545.
22. 22 Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 (suppl A): 45-57.
23. rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La. Oct 17-20,1993: 134 (abst).
24. 24 Highet VS, Schentag JJ, Forrest A, Ballow CH. Antibiotic dosing issues in lower respiratory tract infection: population-derived AUIC is predictive of efficacy. J Antimicrob Chemother 1999; 43: (Suppl A 12): 55-63.
25. 25 Schentag JJ, Vari AJ, Winslade NE, et al. Treatment with aztreonam or tobramycin in critical care patients with gram negative pneumonia. Am J Med 1985; 78 (suppl 2a): 34-41.
26. 26 Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized double blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. Antimicrob Agents Chemother 1994; 38: 547-557.
27. 27 Sanders CC, Sanders WE. Beta lactam resistance in gram-negative bacteria: global trends and clinical Impact. Clin Infect Dis 1992; 15: 824-839.
28. 28 Hyatt JM, Nix DE, Schentag JJ. Pharmacokinetic and pharmacodynamic activity of ciprofloxacin against strains of S. pneumoniae, S. aureus, and P. aeruginosa for which MICs are similar. Antimicrob Agents Chemother 1994; 38: 2730-2737.
29. 29 Chow JW, Fine MJ, Schlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-590.
30. 30 Schentag JJ. Understanding and managing microbial resistance in institutional settings. Am J Health-System Pharm 1995; 52 (suppl 2): S9-S14.
31. 31 Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Diag Microbiol Infect Dis 1992; 15: 37S-42S.
32. 32 Vlasses PH, Bastion WA, Behal R, Sirgo MA. Ceftazidime in the elderly: Economic implications. Ann Pharmacother 1991; 25: 284-288.
33. 33 Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-527.
34. 34 Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271: 1598-1601.
35. 35 ATS Board of Directors. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am J Respir Crit Care Med 1995; 153: 1711-1725.
36. 36 Johansen WG, Pierce AK, Sanford JP, Thomas GD. Nosocomial respiratory infections with gram negative bacilli: the significance of colonization of the respiratory tract. Ann Intern Med 1972; 77: 701-706.
37. 37 Schentag JJ, Smith IL, Swanson DJ, DeAngelis C, Fracasso JE, Vari A, Vance JW. Role for dual individualization with cefmenoxime. Am J Med 1984; 77 (suppl 6a): 43-50.
38. 38 Strenkoski-Nix LC, Nix DE, Forrest A, Schentag JJ. Pharmacodynamic Interactions of ciprofloxacin, piperacillin and piperacillin/tazobactam in volunteer subjects. J Clin Pharmacol 1998; 38: 1063-1071.
39. 39 Schentag JJ, Strenkoski-Nix LC, Nix DE, Forrest A. Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis 1998; 27: 40-46.
40. 40 Nix DE, Wilton JH, Hyatt JC, Thomas J, Strenkoski-Nix LC, Forrest A, Schentag JJ. Pharmacodynamic modeling of the in vitro interaction between cefotaxime and ofloxacin using serum inhibitory tests. Antimicrob Agents Chemother 1997; 41: 1108-1114.
41. 41 Schentag JJ, Plaut ME, Cerra F. Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother 1981; 19: 859-866.
42. 42 Schentag JJ, Cumbo TJ, Jusko WJ, Plaut ME. Gentamicin tissue accumulation and nephrotoxic reactions. JAMA 1978; 240: 2067-2069.
43. 43 Carr JR, Fitzpatrick P, Izzo JL, et al. Changing the infection control paradigm from off line to real time: the experience at Millard Fillmore Hospital. Infect Control Hosp Epidemiol 1997; 18: 255-259.
44. 44 Cohen ML. Epidemiology of drug resistance. Implications for a post antimicrobial era. Science 1992; 257: 1050-1055.